Biopharma

Services

Access our Biomarker Detection AI suite

Unlock the full potential of your cancer research with StratifAI’s proprietary Biomarker Detection AI Suite. Specifically designed for biopharma partners, our suite offers state-of-the-art AI models that derive actionable insights from routinely available histology data. These insights can be directly leveraged to accelerate your drug discovery processes, enabling a faster and more successful development of innovative treatments.

Customized Development of AI tools

At StratifAI, we understand that each biopharma partner has unique needs and objectives. That’s why we offer customized development of AI models to suit your specific requirements. Our team of expert AI researchers, and clinicians will collaborate closely with you to develop tailored AI solutions that can predict your biomarkers of interest using routine clinical data.

Discover Novel Biomarkers

Increase the success rate of your drug development by identifying novel biomarkers that drive treatment response.

Cost Efficiency

Reduce costs associated with traditional biomarker discovery methods by utilizing our advanced AI technology.

Scalable Solution

Our AI suite is designed to scale with your research needs, delivering reliable results for large populations in a matter of days.
Tailored Solutions

Personalize AI models to your specific research objectives, ensuring highly relevant and effective biomarker predictions that meet your needs.

Access to our Expert Network

Benefit from the combined expertise of our AI researchers and clinicians who can assist you with your unique needs.

Reduced Time-To-Market

Accelerate your drug development timeline with our customized AI solutions, which can serve as companion diagnostic tools for your therapeutic candidates.

Enhanced AI performance

Boost the performance of your AI models by integrating our state-of-the-art foundation model, leading to substantially improved results on downstream tasks.

Reduced Dependence on Labeled Data

Utilize the rich and meaningful feature representations provided by our foundation model to drastically decrease the need for rare and time-consuming labeled histology data.

Increased Generalizability

Benefit from training data derived from multiple cohorts, making your models more robust and adaptable to diverse datasets and different cohorts.

We extract crucial insights
from routine data

MSI
Drug
Response
EGFR
KRAS
APC
NRAS
Recurrence
Risk
PIK3CA
STK11
Your Biomarker
of Choice
TP53

Leverage the power of our proprietary AI models to drive innovation and success in your research.

Contact us today to learn more about how our advanced AI technology can support your drug discovery and development efforts.